Menu Close
A shipment of COVID-19 vaccines being unloaded from a plane
A shipment of COVID-19 vaccines supplied by COVAX, the vaccine-sharing programme, arriving in Timor Leste. Antonio Dasiparu/EPA-EFE

COVID vaccine weekly: G7 donations unlikely to bring pandemic to an end by 2022

The dust from the G7 summit has settled and big statements have been made: the leaders of the world’s richest democracies have set the target of ending the pandemic by the close of 2022.

The question is whether their actions match their words. The G7 nations have pledged 1 billion vaccine doses to lower-income nations, but it’s estimated that 11 billion will be needed to raise global immunity levels sufficiently to suppress the coronavirus. There is a clear gap between rhetoric and reality, with this commitment representing a massive failure of ambition and leadership by the G7, says Michael Jennings, reader in international development at SOAS.

Read more: The G7's vaccine pledge: donating 1 billion doses to end the pandemic is far too little – viewpoint

In fact, the whole means of getting sufficient doses to poorer nations needs a rethink, argue Sophie Harman, Eugene Richardson and Parsa Erfani. Sharing leftover vaccines is an unsustainable model, dependent on the whim of individual countries. Covax, the vaccine-sharing initiative, has already shown how donations-based distribution can fall apart. If a donor country suddenly finds itself in need of more vaccine doses, its donations will simply dry up.

A better solution, they argue, would be to bolster the production of vaccine doses by lower-income countries themselves, by waiving intellectual property protection on the vaccines and transferring the necessary technology and know-how from richer countries to poorer ones.

Read more: To end COVID-19 we need vaccine justice for developing countries not outdated charity – viewpoint

This would be difficult, says Klaus Meyer, professor of international business at Western University – but not impossible. Sizable investment would be needed to develop production capacity in countries in Africa, for example. But perhaps the greatest resource needed would be time. Building production capacity might not happen quickly enough to help end the pandemic. But if done now, it could help quash the next one before it gets going.

Read more: A COVID-19 vaccine plant in Africa? This is what it would take to build one

This is our weekly round-up of expert information about the COVID-19 vaccines.
The Conversation, a not-for-profit group, works with a wide range of academics across its global network to produce evidence-based analysis and insights. Get more regular updates from trusted experts by subscribing to our free newsletter .

Meanwhile, the UK government has stated that being vaccinated for COVID-19 will become mandatory for care home workers. Compulsory vaccinations are always contentious, and Dominic Wilkinson and Julian Savulescu at the University of Oxford have considered both sides of the argument.

On the one hand, trying to persuade everyone working in the sector to take a vaccine hasn’t worked: 10% of care staff still aren’t fully vaccinated. Because they are caring for some those most vulnerable to the disease, enforcing vaccination could be deemed proportionate.

But there are also risks – albeit rare ones – that come with COVID-19 vaccines, and at least a quarter of care home staff have already gained some natural immunity through being infected while at work. It’s also not guaranteed that taking a vaccine blocks someone from passing on the coronavirus. The risk-benefit ratio may not therefore be in favour of taking a vaccine for all staff, particularly those who are younger. Enforcing take-up thus feels unfair.

Read more: Should COVID vaccines be compulsory for care home staff? Experts debate

Plus, people with lingering doubts over getting vaccinated may still decide to do so of their own accord. Seeing many other people doing something – such as getting vaccinated for COVID-19 – creates what’s known as “social proof”, says Andrew Chadwick, professor of political communication at Loughborough University. Social proof is a powerful tool generating conformity, so as more and more people get jabbed, we may see hesitancy rates fall anyway.

Read more: Why COVID-19 vaccine hesitancy should fall as more people get the jab

That said, not all hesitancy is easily overcome. New research estimates that as many as 10% of those who are vaccine hesitant in the UK could be so not for any ideological reason, or because of any health concern, but simply because they have a phobia of needles. But the best solution in this scenario, argues Daniel Freeman, professor of clinical psychology of the University of Oxford, isn’t making vaccines mandatory – it’s attacking the root cause of hesitancy with tried-and-tested treatments for phobias.

Read more: Needle phobia could be the cause of 10% of COVID vaccine hesitancy in the UK – new research

Get the latest news and advice on COVID-19, direct from the experts in your inbox. Join hundreds of thousands who trust experts by subscribing to our newsletter.

Want to write?

Write an article and join a growing community of more than 174,400 academics and researchers from 4,804 institutions.

Register now